

**Online appendix. Donaldson M, Norbeck AO. Adverse events in patients initiated on dabigatran etexilate therapy in a pharmacist-managed anticoagulation clinic. Pharmacy Practice 2013 Apr-Jun;11(2):90-95.**

**Patients experiencing an adverse drug event (ADE) while on dabigatran etexilate therapy.**

Patient No.	Age (years) at Time of Event	Sex	Weight (kgs)	Dose	CrCl (mL/min) based on Ideal Body Weight	CrCl (mL/min) based on Actual Body Weight	Brief description of ADE	ADE	Interacting Medication
1	63	M	101.8	150 mg BID	75.6	96.3	Rectal bleeding	Bleeding – CRNM**	
2	68	F	76.4	150 mg BID	49.8	57.5	GI intolerance/dyspepsia	Nonbleeding - CRNM	
3	71	M	84.5	150 mg BID	60.1	67.5	GI bleed	Bleeding - CRNM	
4	78	M	94.1	150 mg BID	63.5	65.3	Edema	Nonbleeding - CRNM	amiodarone
5	74	M	93.6	150 mg BID	65	83.3	Hematuria	Bleeding - CRNM	
6	86	F	65.9	150 mg BID	30.6	37.2	GI bleed	Bleeding - Major	
7	75	F	65.0	150 mg BID	33.9	40.2	Dyspepsia, abdominal pain	Nonbleeding - CRNM	
8	54	M	90.0	150 mg BID	72.5	86.7	Rectal bleeding	Bleeding - CRNM	
9	70	M	159.1	150 mg BID	59	124.7	Epistaxis	Bleeding - CRNM	dronedrone ASA 81mg qd
10	81	F	77.3	150 mg BID	37	52.3	Dyspnea	Nonbleeding - CRNM	
11***	79	F	91.8	150 mg BID	50.7	81.6	CVA	Nonbleeding - Serious	
12	77	M	93.2	150 mg BID	57.5	73.5	Bleeding hemorrhoids	Bleeding - CRNM	
13	75	M	121.8	150 mg BID	55.4	76.5	Knee effusion	Bleeding - CRNM	
14	71	F	90.0	150 mg BID	41.6	64.3	Severe itching	Nonbleeding - CRNM	dronedrone
15	89	F	48.6	150 mg BID	21.8	21.8	Severe abdominal pain, diarrhea	Nonbleeding - CRNM	amiodarone
16	68	M	131.8	150 mg BID	72.7	116.6	GI bleed	Bleeding - Major	
17	79	M	85.0	150 mg BID	51.4	58.1	Rectal bleeding; epistaxis	Bleeding - CRNM	verapamil
18	58	M	101.8	150 mg BID	69.2	93.5	Severe dyspepsia	Nonbleeding - CRNM	amiodarone
19	74	F	114.1	150 mg BID	33.8	66.3	Bleeding bowels; extensive rash	Bleeding - CRNM	
20	89	M	76.8	150 mg BID	29.9	34.9	Blood in stool	Bleeding - CRNM	amiodarone ASA 81mg qd
21	54	F	95.0	150 mg BID	65.4	104.3	Persistent nausea; dyspepsia	Nonbleeding - CRNM	ASA 81mg qd
22	71	M	102.7	150 mg BID	57.1	73.4	Dyspepsia	Nonbleeding - CRNM	
23	82	F	90.9	150 mg BID	40.1	47.6	Cardiac tamponade	Bleeding - Major	dronedrone

Patient No.	Age (years) at Time of Event	Sex	Weight (kgs)	Dose	CrCl (mL/min) based on Ideal Body Weight	CrCl (mL/min) based on Actual Body Weight	Brief description of ADE	ADE	Interacting Medication
24	58	M	99.1	150 mg BID	83.9	91.8	Rectal bleeding	Bleeding - CRNM	dronederone
25	81	F	87.7	150 mg BID	21.5	36.8	Severe nausea/abdominal pain	Nonbleeding - CRNM	dronederone
26	87	F	46.8	150 mg BID	18.8	18.8	Severe erosive esophagitis	Nonbleeding - Serious	amiodarone
27	83	M	90.9	150 mg BID	49	69.9	Dyspepsia	Nonbleeding - CRNM	
28	67	M	101.4	150 mg BID	62.2	76.7	Muscle aches	Nonbleeding - CRNM	ASA 81mg qd
29	80	F	95.5	150 mg BID	35.7	57	Upper GI bleed	Bleeding - Major	dronederone
30*	82	M	117.3	150 mg BID	28.4	43	Rectal bleeding, epistaxis	Bleeding - CRNM	ASA 325mg qd
31*	77	M	100.5	150 mg BID	56.2	85.4	Myocardial infarction, death	Nonbleeding - Serious	
32	66	M	107.7	150 mg BID	81.6	120.3	Large pericardial effusion	Bleeding - Major	
33	81	F	69.1	150 mg BID	32.3	43.5	GI bleed	Bleeding - Major	
34	76	M	123.6	150 mg BID	61	106.7	Bleeding hemorrhoids, dyspepsia	Bleeding - CRNM	
35	77	M	79.1	150 mg BID	44.7	47.7	Dyspepsia	Nonbleeding - CRNM	
36	68	M	121.8	150 mg BID	66.4	118.3	GI Bleed	Bleeding - Major	ASA 81mg qd
37	79	F	62.3	150 mg BID	35	43.6	Severe abdominal pain, dyspepsia	Nonbleeding - CRNM	ASA 81mg qd
38	76	F	99.1	150 mg BID	59.6	92.4	Muscle weakness, vision changes	Nonbleeding - CRNM	
39	36	M	98.2	150 mg BID	81.2	105.9	Severe dyspepsia	Nonbleeding - CRNM	dronederone
40	72	M	90.5	150 mg BID	26.3	32.6	Bleeding, thrombocytopenia	Bleeding - CRNM	
41	73	F	82.7	150 mg BID	43.8	63.5	Bleeding hemorrhoids	Bleeding - CRNM	
42	74	F	103.2	150 mg BID	50.6	87.4	Severe dyspepsia	Nonbleeding - CRNM	
43	76	F	118.2	150 mg BID	42.7	79	Dyspnea, dyspepsia	Nonbleeding - CRNM	
44	64	M	125.5	150 mg BID	75.8	103.3	Generalized rash	Nonbleeding	
45*	58	M	80.0	150 mg BID	93.2	99	Upper GI bleed; death	Bleeding - Major	
46	78	F	89.1	150 mg BID	39.9	57.7	Dyspepsia, back pain	Nonbleeding	
47	75	M	98.6	150 mg BID	62	86.4	GI bleed	Bleeding - Major	
48	64	M	136.4	150 mg BID	81.1	127.4	Dyspepsia	Nonbleeding	dronederone
49	86	F	70.5	75 mg BID	31.5	48.9	Severe abdominal pain,	Nonbleeding	

Patient No.	Age (years) at Time of Event	Sex	Weight (kgs)	Dose	CrCl (mL/min) based on Ideal Body Weight	CrCl (mL/min) based on Actual Body Weight	Brief description of ADE	ADE	Interacting Medication
							dyspepsia		
50	89	F	59.1	150 mg BID	35.9	35.9	Generalized rash	Nonbleeding	
51*	82	M	93.6	75 mg BID	30.6	38.1	Myocardial infarction, death	Nonbleeding - Serious	verapamil
52	74	M	81.4	150 mg BID	50.6	60.2	Chest pain, abdominal pain requiring hospitalization	Nonbleeding - Serious	
53	81	F	85.9	75 mg BID	38.5	58.1	Severe abdominal/chest pain requiring hospitalization	Nonbleeding - Serious	ASA 81mg qd
54	83	F	72.3	150 mg BID	36.6	52.9	Severe dyspepsia	Nonbleeding	

\* Patients who expired while on dabigatran therapy.

\*\*CRNM: Clinically-Relevant Nonmajor Bleeding.

\*\*\*Patient expired 6 days after self-discontinuing dabigatran etexilate.